198M-1
CD123 (6H6) Mouse Monoclonal Antibody
Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych
About This Item
Kod UNSPSC:
12352203
NACRES:
NA.41
Polecane produkty
pochodzenie biologiczne
mouse
Poziom jakości
100
500
białko sprzężone
unconjugated
forma przeciwciała
culture supernatant
rodzaj przeciwciała
primary antibodies
klon
6H6, monoclonal
opis
For In Vitro Diagnostic Use in Select Regions (See Chart)
Formularz
buffered aqueous solution
reaktywność gatunkowa
human
opakowanie
vial of 0.1 mL concentrate (198M-14)
vial of 0.5 mL concentrate (198M-15)
bottle of 1.0 mL predilute (198M-17)
vial of 1.0 mL concentrate (198M-16)
bottle of 7.0 mL predilute (198M-18)
producent / nazwa handlowa
Cell Marque®
metody
immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:25-1:100
izotyp
IgG1κ
kontrola
blastic plasmacytoid dendritic cell neoplasm
Warunki transportu
wet ice
temp. przechowywania
2-8°C
wizualizacja
cytoplasmic
Powiązane kategorie
Opis ogólny
Blastic plasmacytoid dendritic cell neoplasm (BPDCN), previously known as CD4+/CD56+ hematodermic neoplasm or blastic NK-cell lymphoma, is a malignant neoplasm composed of immature hematopoietic precursors of plasmacytoid dendritic cells. The most frequent manifestation is a skin lesion, bone marrow involvement, and regional lymphadenopathy. Myeloid leukemia cutis (LC), myeloid sarcoma, and large aggressive B cell lymphomas should be differentiated from BPDCN. Recently, it has been reported that these entities can be distinguished by using immunohistochemistry (IHC) in paraffin-embedded tissue sections. In this study, 23 myeloid LC and 12 BPDCN cases were evaluated using a panel of antibodies against CD123, TCL1, CD4, CD56, MPO and CD33; with results as follows: anti-CD123 stained 4 cases (17%) of myeloid LC and 10 cases (83%) of BPDCN; anti-TCL-1 stained 2 cases (9%) of myeloid LC and 9 (82%) of 11 cases of BPDCN; anti-CD4 stained 2 cases (9%) of LC and all 12 cases (100%) of BPDCN; anti-CD56 stained 12 cases (52%) of LC and all 12 cases (100%) of BPDCN; anti-myeloperoxidase stained 7 cases (30%) of LC and 0 cases (0%) of BPDCN. Anti-CD33 was not helpful; it stained 18 (78%) cases of LC and 11 cases (92%) of BPDCN. The results indicated that a panel that includes antibodies against CD4, CD56, CD123, and TCL-1 can appropriately distinguish between myeloid LC and BPDCN.
CD123 IHC expression has been studied in 157 acute myeloid leukemia (AML) bone marrow biopsies and/or marrow particle preparations, and correlated with the morphologic, immunophenotypic, and cytogenetic features and with the presence of FLT3-ITD and NPM1 mutations. CD123 IHC expression has been seen in 40% of AML, across a wide spectrum of 2008 World Health Organization subtypes and was most frequent within the intermediate risk group. Compared with CD123 IHC negative AML, CD123 IHC positive AML demonstrated higher marrow blast percentages (median 69%), monocytic differentiation (33/63 cases), and CD34 negativity (29/63 cases). 83% (25/30) FLT3-ITD-mutated AML were CD123+ and 62% (18/29) NPM1-mutated cases were CD123 IHC+ (P=0.0052). CD123 IHC+AML presents with characteristic pathologic features, some of which may be related to underlying FLT3-ITD and/or NPM1 mutations.
CD123 IHC expression has been studied in 157 acute myeloid leukemia (AML) bone marrow biopsies and/or marrow particle preparations, and correlated with the morphologic, immunophenotypic, and cytogenetic features and with the presence of FLT3-ITD and NPM1 mutations. CD123 IHC expression has been seen in 40% of AML, across a wide spectrum of 2008 World Health Organization subtypes and was most frequent within the intermediate risk group. Compared with CD123 IHC negative AML, CD123 IHC positive AML demonstrated higher marrow blast percentages (median 69%), monocytic differentiation (33/63 cases), and CD34 negativity (29/63 cases). 83% (25/30) FLT3-ITD-mutated AML were CD123+ and 62% (18/29) NPM1-mutated cases were CD123 IHC+ (P=0.0052). CD123 IHC+AML presents with characteristic pathologic features, some of which may be related to underlying FLT3-ITD and/or NPM1 mutations.
Jakość
 IVD |  IVD |  IVD |  RUO |
Powiązanie
CD123 Positive Control Slides, Product No. 198S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).
Postać fizyczna
Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide
Uwaga dotycząca przygotowania
Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.
Inne uwagi
For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com
Informacje prawne
Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany
Ta strona może zawierać tekst przetłumaczony maszynowo.
Nie możesz znaleźć właściwego produktu?
Wypróbuj nasz Narzędzie selektora produktów.
Kod klasy składowania
12 - Non Combustible Liquids
Klasa zagrożenia wodnego (WGK)
WGK 2
Temperatura zapłonu (°F)
Not applicable
Temperatura zapłonu (°C)
Not applicable
Wybierz jedną z najnowszych wersji:
Certyfikaty analizy (CoA)
Lot/Batch Number
Nie widzisz odpowiedniej wersji?
Jeśli potrzebujesz konkretnej wersji, możesz wyszukać konkretny certyfikat według numeru partii lub serii.
Masz już ten produkt?
Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.
Facchetti F, et al.
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue, 145-147 (2008)
Marian Rollins-Raval et al.
Applied immunohistochemistry & molecular morphology : AIMM, 21(3), 212-217 (2012-08-24)
FLT3-ITD and NPM1 mutation testing in acute myeloid leukemia (AML) plays an important role in prognostic risk stratification, especially within the intermediate cytogenetic risk group. Molecular studies require adequate fresh material and are typically performed on a dedicated aspirate specimen
Facchetti F, et al.
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue, 145-147 (2008)
Danielle M P Cronin et al.
American journal of clinical pathology, 137(3), 367-376 (2012-02-18)
Myeloid leukemia cutis (LC) and blastic plasmacytoid dendritic cell neoplasm (BPDCN) are morphologically indistinguishable malignancies that frequently manifest in the skin. Separating myeloperoxidase-negative LC from BPDCN may be particularly challenging. We identified a panel of immunohistochemical stains to distinguish myeloid
Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.
Skontaktuj się z zespołem ds. pomocy technicznej